FY2017 EPS Estimates for FibroGen, Inc (FGEN) Increased by Analyst

FibroGen, Inc (NASDAQ:FGEN) – Equities research analysts at Leerink Swann raised their FY2017 earnings estimates for shares of FibroGen in a report released on Thursday. Leerink Swann analyst G. Porges now forecasts that the biopharmaceutical company will post earnings of ($1.74) per share for the year, up from their previous forecast of ($1.91). Leerink Swann has a “Outperform” rating and a $82.00 price objective on the stock. Leerink Swann also issued estimates for FibroGen’s Q4 2017 earnings at ($0.28) EPS, FY2018 earnings at ($2.14) EPS, FY2019 earnings at ($0.52) EPS, FY2020 earnings at $1.97 EPS and FY2021 earnings at $4.35 EPS.

Several other brokerages have also issued reports on FGEN. Mizuho began coverage on shares of FibroGen in a report on Wednesday, October 4th. They issued a “neutral” rating and a $61.00 price target for the company. Stifel Nicolaus reaffirmed a “buy” rating and issued a $80.00 target price on shares of FibroGen in a research note on Thursday, September 14th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $75.00 target price on shares of FibroGen in a research note on Tuesday, September 12th. William Blair reaffirmed an “outperform” rating on shares of FibroGen in a research note on Wednesday, August 9th. Finally, Goldman Sachs Group, Inc. (The) lowered shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 target price for the company. in a research note on Friday, July 21st. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. FibroGen currently has a consensus rating of “Buy” and an average price target of $65.67.

TRADEMARK VIOLATION WARNING: “FY2017 EPS Estimates for FibroGen, Inc (FGEN) Increased by Analyst” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://ledgergazette.com/2017/11/13/fy2017-eps-estimates-for-fibrogen-inc-fgen-increased-by-analyst.html.

FibroGen (FGEN) opened at $47.12 on Monday. FibroGen has a fifty-two week low of $19.25 and a fifty-two week high of $60.15. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.16.

In related news, VP Pat Cotroneo sold 2,851 shares of the company’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $49.45, for a total value of $140,981.95. Following the completion of the transaction, the vice president now directly owns 157,405 shares of the company’s stock, valued at approximately $7,783,677.25. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Kalevi Kurkijarvi sold 2,000 shares of the company’s stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $40.74, for a total transaction of $81,480.00. Following the completion of the transaction, the director now directly owns 30,000 shares of the company’s stock, valued at $1,222,200. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 428,118 shares of company stock valued at $22,355,896. Company insiders own 14.90% of the company’s stock.

A number of large investors have recently modified their holdings of the business. SG Americas Securities LLC lifted its position in FibroGen by 6.5% during the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 412 shares in the last quarter. Cornerstone Capital Management Holdings LLC. lifted its position in FibroGen by 1.7% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 29,090 shares of the biopharmaceutical company’s stock worth $939,000 after buying an additional 474 shares in the last quarter. Principal Financial Group Inc. lifted its position in FibroGen by 0.4% during the 1st quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock worth $3,354,000 after buying an additional 504 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in FibroGen by 15.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 696 shares in the last quarter. Finally, Tudor Investment Corp ET AL lifted its position in FibroGen by 7.1% during the 2nd quarter. Tudor Investment Corp ET AL now owns 12,095 shares of the biopharmaceutical company’s stock worth $391,000 after buying an additional 799 shares in the last quarter. 46.93% of the stock is currently owned by hedge funds and other institutional investors.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply